Back to Search
DENISE YARDLEY, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1801829114IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
34639(TN)
CMS Specialties
PrimaryHEMATOLOGY/ONCOLOGY
Education
MEDICAL COLLEGE OF GEORGIA SCHOOL OF MEDICINE
Class of 1988
Research & Publications (20)
Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer.
PMID 19661042·Clin Breast Cancer·2009
3-trial
Proactive management of adverse events maintains the clinical benefit of ixabepilone.
PMID 19411315·Oncologist·2009
6-review
Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
PMID 19073502·Clin Breast Cancer·2008
6-review
A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer.
PMID 18952556·Clin Breast Cancer·2008
3-trial
A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer.
PMID 18650154·Clin Breast Cancer·2008
3-trial
Integrating gemcitabine into breast cancer therapy.
PMID 15685825·Oncology (Williston Park)·2004
6-review
Gemcitabine and docetaxel in metastatic and neoadjuvant treatment of breast cancer.
PMID 15199531·Semin Oncol·2004
6-review
Gemcitabine and taxanes as a new standard of care in breast cancer.
PMID 14754467·Clin Breast Cancer·2004
6-review
Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.
PMID 19299236·Clin Breast Cancer·2009
3-trial
A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer.
PMID 19294387·Cancer Chemother Pharmacol·2009
3-trial
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
PMID 19228746·Clin Cancer Res·2009
3-trial
Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network.
PMID 17922972·Clin Lung Cancer·2007
3-trial
Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
PMID 17805064·J Thorac Oncol·2007
3-trial
Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancer.
PMID 17409825·J Thorac Oncol·2006
3-trial
Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
PMID 16179100·Clin Lung Cancer·2005
3-trial
Loss of FHIT expression in breast cancer is correlated with poor prognostic markers.
PMID 16030101·Cancer Epidemiol Biomarkers Prev·2005
8-other
Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer.
PMID 16001992·Clin Breast Cancer·2005
3-trial
Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial.
PMID 15561808·Oncologist·2004
3-trial
Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches.
PMID 15221580·Support Care Cancer·2004
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 250 25TH AVE N, STE 100
NASHVILLE, TN 37203 - Phone
- (615) 329-0570
Quick Facts
- NPI
- 1801829114
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 38
- Publications
- 20
Are you this provider?
Claim Your Profile